- Home
- MIRA vs KLRS Comparison
MIRA vs KLRS Comparison
Compare MIRA & KLRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MIRA | KLRS |
|---|---|---|
| Founded | 2020 | 2019 |
| Country | United States | United States |
| Employees | 5 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 44.0M | 46.0M |
| IPO Year | 2023 | N/A |
Fundamental Metrics
Financial Performance| Metric | MIRA | KLRS |
|---|---|---|
| Price | $1.12 | $6.12 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $20.67 |
| AVG Volume (30 Days) | ★ 158.4K | 41.4K |
| Earning Date | 05-13-2026 | 03-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 20.31 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.81 | $2.14 |
| 52 Week High | $2.45 | $11.88 |
Technical Indicators
Market Signals| Indicator | MIRA | KLRS |
|---|---|---|
| Relative Strength Index (RSI) | 46.96 | 26.70 |
| Support Level | N/A | $4.54 |
| Resistance Level | $1.28 | $7.20 |
| Average True Range (ATR) | 0.08 | 0.77 |
| MACD | -0.01 | -0.36 |
| Stochastic Oscillator | 67.65 | 4.04 |
Price Performance
Historical ComparisonAbout MIRA MIRA Pharmaceuticals Inc.
Mira Pharmaceuticals Inc is a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a broad range of neurologic and neuropsychiatric disorders. The company's novel oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia.
About KLRS Kalaris Therapeutics Inc.
Kalaris Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for prevalent retinal diseases. The company is developing TH103, a novel, clinical-stage anti-vascular endothelial growth factor (VEGF) drug, engineered to potentially provide longer-lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body's native, highest affinity VEGF receptor 1.